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In the last decades, significant progress in research and clinics has been made to offer possible innovative therapeutics for the
management of allergic diseases. However, current allergen immunotherapy shows limitations concerning the long-term efficacy
and safety due to local side effects and risk of anaphylaxis. Thus, effective and safe vaccines with reduced dose of allergen have been
developed using adjuvants. Nevertheless, the use of adjuvants still has several disadvantages, which limits its use in human vaccines.
In this context, several novel adjuvants for allergen immunotherapy are currently being investigated and developed. Currently,
nanoparticles-based allergen-delivery systems have received much interest as potential adjuvants for allergen immunotherapy. It
has been demonstrated that the incorporation of allergens into a delivery system plays an important role in the efficacy of allergy
vaccines. Several nanoparticles-based delivery systems have been described, including biodegradable and nondegradable polymeric
carriers. Therefore, this paper provides an overview of the current adjuvants used for allergen immunotherapy. Furthermore,
nanoparticles-based allergen-delivery systems are focused as a novel and promising strategy for allergy vaccines.
1. Introduction
Over the past few years, a large increase in the prevalence
of allergic diseases has been reported [1]. Epidemiological
studies report that allergic sensitization is detected in
more than 25% of the general population, particularly in
industrialized countries [2]. Nowadays, allergy is defined as
immediate reactions (also known as type I hypersensitivity)
against foreign antigens, accompanied by a high IgE stimulus
[3]. Various environmental proteins, namely, allergens, are
recognized as foreign elements by the immune system of
some individuals. Allergic diseases include rhinitis (hay
fever), asthma, food allergy, allergic skin inflammation,
ocular allergy, and anaphylaxis [4].
The etiology of allergic immune responses is complex,
and several factors, including environmental and genetics,
have been described as triggers of allergic diseases [5].
Recently, different gene polymorphisms were identified, and
they also affect the individual predisposition to develop
allergy, known as atopy [6–9]. However, a genetic predis-
position alone does not explain the increased prevalence of
these diseases in the last decades. It has been proposed that
this increase seems to be attributed to environmental factors
acting on a genetic basis [7].
Since the first description of allergy in early 1900s, sig-
nificant progress to research and clinics has been made in
offer possible innovative therapeutics for the management
of allergic diseases [10–13]. Remarkable advances in allergen
immunotherapy include the use of purified allergens-based
vaccines [14], blocking antibodies [15], the recombinant
interleukins administration [16, 17], DNA vaccines [18],
and gene therapy [19]. However, current approaches show
limitations concerning the long-term efficacy and safety due
to local side effects and risk of anaphylaxis. Effective and
safe vaccines require the use of effective and safe adjuvants
[20–23]. Therefore, this paper provides an overview of
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Figure 1: Mechanisms of allergic responses. Allergic response is constituted by two phases: an early phase (a) of initial sensitization
and memory activation and a later phase response (b) after re-exposure to allergen, resulting in release of inflammatory mediators as a
consequence of allergen cross-linking basophil/mast cell-bound specific IgE.
the currently adjuvants used for allergen immunotherapy.
Furthermore, nanoparticles-based allergen-delivery systems
are focused and discussed as a novel and promising strategy
for allergy vaccines.
2. Immunological Aspects of Allergic Diseases
Allergic diseases are immunologic disorders characterized by
an imbalance in the responses of activation of CD4+ T helper
(TH1 and TH2) and T regulatory (TReg) cells [24]. Among
the many cells involved in allergic reaction, CD4+ T cells
play a central role in the immune response against allergens.
In atopic individuals, functional polarization of allergen-
specific response of CD4+ T cells and cytokine profile is TH2-
polarized (Figure 1). In contrast, activated allergen-specific T
cells from nonatopic subjects are TH1 polarized accompanied
by secretion of IFN-γ and IL-2. Allergic inflammatory
cytokines are secreted, particularly IL-4, IL-5, and/or IL-13.
This latter is an importantmediator of allergic inflammation.
IL-13 promotes immunoglobulin class switching for IgE
production and increases both recruitment and activation
of inflammatory cells such as eosinophils, mast cells, and
basophils [25, 26]. Recently, several studies suggest that TH17
and TReg also have a significant role in the development of
allergic diseases [27, 28]. Current studies have demonstrated
that these novel T cells, producing IL-17 and IL-10, regulate
innate immunity by signal transduction, which mitigates
their proinflammatory function (Figure 1) [29].
The mechanism of the allergic reaction is characterized
by two phases: the initial sensitization phase, which is
followed by the second phase that is characterized by imme-
diate hypersensitivity symptoms. After an initial exposure
(Figure 1(a)), TH2 pathway is initiated by the uptake of
allergens by professional antigen-presenting cells (APCs)
that present peptides on MHC class II molecules to naive
CD4+ T cells, which activate a cell response. Thereafter,
high amounts of specific IgE antibodies are produced and
bind to high affinity IgE receptor (FcεRI) in membranes
of circulating basophils and mast cells that reside in skin
and mucous membranes. Upon re-exposure to the allergen
(Figure 1(b)), an immediate hypersensitivity response is
triggered as consequence of cross-linking of the allergen
with two molecules of mast cell-bound IgE. This signal
stimulates the release of histamine and other inflammatory
mediators such as serine proteases, platelet activating factor,
cytokines, leukotrienes and prostaglandins. These mediators
increase vascular permeability and promote mucus produc-
tion, which are responsible for the symptoms and signs of
allergic diseases [25, 26].
3. Allergen-Specific Immunotherapy
Allergen-specific immunotherapy (SIT) involves the admin-
istration of increasing doses of allergen(s) in order
to obtain a hyposensitization and long-term relief of
symptoms occurring after natural allergen exposure. SIT
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have been considered an efficient, safe, and long-term-
benefit approach, which may be combined with appro-
priate allergen-avoidance strategies. However, discovery of
allergen-specific immunotherapy raised a number of crucial
questions regarding the route of administration, the dose
response relationship, and the intervals between administra-
tions [30].
Nowadays, several immunotherapeutic strategies have
been achieved to modulate the immune system by different
pathways [13]. Advances in the standardization of allergenic
composition of vaccines, optimal dose of allergen and, above
all, clinical studies that support their effectiveness are crucial
not only to achieve more effective and safe vaccines, but also
to provide greater dosing convenience [31].
3.1. Mechanisms of Allergen-Specific Immunotherapy. It has
been established that an immune-tolerant state represents an
essential step for a successful immunotherapy [32]. Several
findings suggest that SIT acts through an immunomodu-
latory activity (Figure 2), changing the TH1, TH2, TH17,
and TReg cell differentiation [33–35]. Following SIT, an
increase in CD8+ cells and TH1/TH0 ratio are observed.
Also, a decrease in TH2/TH0 ratio takes place. Additionally,
a change in cytokine response with production of IL-4 and
IFN-γ (IL-4 to IFN-γ) is observed as result of downregu-
lation of TH2 or increased TH1 response. In this context,
the generation of allergen-specific TReg cells (producing
IL-10 and TGF-β) suppressed proliferative and cytokine
responses, initiating peripheral T-cell tolerance. In addition,
the number of TH2 cells such as basophils and eosinophils
is reduced at the allergen exposition sites (e.g., mucosa and
skin), which reduces the IgE-mediated release of histamine
by basophils [32–34].
Usually, SIT induces a transient increase in serum IgE,
which decreases during the course of the treatment. Success-
ful SIT is also associated with a high increase (10 to 100-
fold) in IgG blocking antibodies such as IgG4 and IgG1. IgG4
acts by capturing the allergen before it crosslinks with the
IgE that is bound on the surface IgE receptors of mast cells
and basophils, inhibiting its activation. Still, IgG4 antibodies
have anti-inflammatory activity through inhibition of the
production of other IgG subtypes [35].
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Recently, the counterregulatory role of IL-10 has been
demonstrated. It is secreted by TReg cells during SIT, which
modulates isotype formation and also change the response
from an IgE to an IgG4-dominated phenotype. Other
indirect function of TReg cells is the suppression of TH17 cells,
accompanied by a decrease in IL-17 secretion [36].
3.2. Routes of Administration. Lately, several routes for aller-
gen delivery have been assessed in immunotherapy. Since
its discovery, the traditional SIT has been commonly given
subcutaneously with high clinical efficacy [30]. However,
subcutaneous immunotherapy (SCIT) is associated with a
significant risk of severe adverse events [37, 38]. Thus,
efforts have been done towards alternative routes (local and
noninjection) for allergen delivery [39].
In the 1980s, the sublingual route appeared as a promis-
ing noninjection route [40]. Sublingual immunotherapy
(SLIT) was regarded as an efficient and safe route. Usually,
SLIT is recommended for patients with severe adverse
reactions to conventional SCIT [41]. Similarly, local nasal
immunotherapy (LNIT) proved to be effective and safe.
However, the exact mechanisms of action and optimal dose
of both SLIT and LNIT has not been established yet [39].
These noninjection routes were proposed by the World
Health Organization (WHO) as viable alternatives to the
subcutaneous route [42]. On the other hand, clinical efficacy
of oral immunotherapy (OIT) was achieved with high doses
of allergen. This has induced to a major research on the
development of new mucosal adjuvants, discussed in the
following section.
4. Adjuvants for Allergen Immunotherapy
The overall goal in allergen vaccine development is improv-
ing both clinical efficacy and safety. Nevertheless, the use
of high amount of allergen on allergen immunotherapy is
limited by a significant risk of allergic reactions [42]. Thus,
effective and safe vaccines with reduced dose of allergen
have been developed using adjuvants. Adjuvants (from Latin,
adjuvare, aid) are defined as heterogeneous compounds that
enhance the immune response against to coadministered
antigens [43].
Ideally, adjuvants for allergy immunotherapy should
stimulate a TH1 immune response without inducing autoim-
munity and should not be mutagenic, carcinogenic, and
teratogenic. Besides, optimal adjuvants need to be apyro-
genic and stable in the vaccine formulation [44]. Despite
the undeniable progress in this area, the use of adjuvants
still has several disadvantages, which limits its use in human
vaccines. Therefore, the benefits and risks related to the
use of adjuvants for allergy immunotherapy need to be
counterbalanced [45]. In this context, several novel adjuvants
for allergen immunotherapy are currently being investigated
and developed [43].
4.1. Mechanisms of Action. Traditionally, adjuvants exert
their effects in different ways: the depot effect, the targeting to
antigen-presenting cells, and the nonspecific modulation of
immune system [43]. The use of allergen extracts adsorbed to
adjuvants protects the antigen from enzymatic degradation.
On the other hand, depot formation entraps the antigen
and provides its slow release. The persistence of the antigen
increases the recruitment of APCs in the injection site,
which triggers a prolonged inflammatory response. Then, the
recruitment of competent cells activates innate and adaptive
immune system.
Adjuvants can be divided into two groups according
to their mechanisms of action as delivery systems and im-
munomodulatory adjuvants. However, some compounds
can act by both mechanisms simultaneously [45–47].
4.2. Traditional Adjuvants. Hundreds of compounds and
molecules have been extensively evaluated as adjuvants
[45]. Aluminium salts and emulsions are traditionally used
as general immunologic adjuvants. Recently, liposomes,
immunostimulating complexes (ISCOMs), oligonucleotides,
andmicroorganisms-derived adjuvants (i.e., MPL) have been
introduced as novel adjuvants in allergy vaccines [44, 46–48].
4.2.1. Aluminium Hydroxide. Aluminium salts (alum) rep-
resents the most commonly used adjuvant in human vac-
cines. Francis and Durham showed that alum-precipitated
diphtheria toxoid was more immunogenic than an aqueous
toxoid [44]. Alum-adsorbed allergen extracts induce a strong
TH2 response by a depot effect and also stimulates the
activation of APCs, independent of Toll-like receptor (TLR)
signalling, but dependent of NLR (NALP3) inflammasome
[46]. Alum is the most common and safe adjuvant for injec-
tion immunotherapy in humans. However, some problems
were reported after use of alum in allergic and prophylactic
vaccines. These drawbacks include the enhanced sensitivity
to alum and local granuloma formation at injection sites.
Yet, tolerance induction has been observed after the use
of aluminium. Thus, it seems to be rational to consider
replacing alum compounds with other more inert molecules
for the treatment of type I hypersensitivity [49].
4.2.2. Emulsions. Depot adjuvants based on Freund’s adju-
vants have been used in experimental studies and introduced
in the clinic. Usually, the allergens are incorporated in
a water-phase followed by the addition of oil and an
emulsifying agent to form an emulsion. This allergen dosage
forms have often a good immunogenic profile, with high
efficacy, and prevented treatment-induced anaphylactic side
effects. Nevertheless, frequent local reactions have limited the
use of emulsions on long-term human prophylactic vaccines
[46].
4.2.3. Liposomes. Liposomes are synthetic spheres based
on a bilayer structure of phospholipids, which allow the
encapsulation of hydrophilic antigens [50]. Liposomes act
as both delivery carrier and immunomodulators. However,
their low stability and manufacturing problems limited
the use of these systems as adjuvants in human vaccines
[46, 48].
Journal of Biomedicine and Biotechnology 5
4.2.4. Monophosphoryl Lipid A. Currently, novel adjuvants
derived from Gram-negative bacterial cell components
have been investigated. Monophosphoryl lipid A (MPL;
Coriza, USA), a purified lipopolysaccharide extracted from
Salmonella minnesota, has been used as adjuvant in allergy
vaccines [44]. MPL increases the activation of dentritic cells
and T cells, inducing a shift in cytokine production with
a potent TH1 response [45]. In addition, MPL has been
shown to enhance both mucosal and systemic immunity
after intranasal administration. Clinically, SIT with MPL has
shown good efficacy and attenuated toxicity [44, 51].
4.2.5. ISCOMs. Immune stimulating complexes (ISCOMs)
are spherical complexes of about 40 nm, with a strong
negative charge, composed of saponin, cholesterol and phos-
pholipids. The micelles consist of three layers, hydrophilic-
hydrophobic-hydrophilic. ISCOMs-incorporated antigens
can trigger humoral, mucosal, and cellular immune re-
sponses [48, 52].
4.2.6. Oligonucleotides. Synthetic oligonucleotides contain-
ing immunostimulatory CpG (ISS) motifs present a strong
induction of TH1 response. Conjugation of ISS with aller-
gen showed enhancement in its immunogenicity and also
reduced its allergenicity [53]. Moreover, it caused an increase
in the activation of both dendritic and T cells, which induced
a shift in cytokine production to a TH1 profile [54].
4.2.7. Particulate Delivery Systems. Particulate delivery sys-
tems belong to the category of adjuvants that facilitate
the antigen uptake by APCs or by increasing the influx
of professional APCs into the injection site. Among the
different types of particulated delivery systems, polymer
nanoparticles are a group of delivery systems with interesting
abilities as adjuvants for both conventional and mucosal
vaccination, since they can enhance the delivery of the loaded
antigen to the gut lymphoid cells due to their ability to
be captured and internalized by cells of the GALT. We will
discuss in more detail the use of polymeric nanoparticles as
adjuvants in the following section.
5. Nanoparticles-Based
Allergen-Delivery Systems
Currently, nanoparticles-based allergen-delivery systems
have received much interest as potential adjuvants for
allergen immunotherapy [55]. It has been demonstrated that
incorporation of allergens into a delivery system plays an
important role in the efficacy of allergy vaccines. In the last
years, several nanoparticles-based delivery systems have been
described, including biodegradable and nonbiodegradable
polymeric carriers [44, 45].
5.1. Biodegradable Polymeric Nanoparticles. Polymeric nano-
particles are colloidal carriers that vary in size from 10 to
1000 nm [56]. They can be divided into two categories:
nanocapsules and nanospheres. Nanocapsules are vesicular
systems in which the drug is confined to a cavity surrounded
by a polymermembrane, whereas nanospheres are polymeric
matrix in which the drug is physically and uniformly
dispersed. Obtaining one or another type of nanoparticle
depends on the preparation method used [57].
Over the last thirty years, different types of polymers and
copolymers have been used to design nanoparticles. Among
them, biodegradable polymers are the most used as great
promise the field of drug-delivery systems. These types of
nanoparticles provide controlled/sustained release proper-
ties, subcellular size, and biocompatibility with tissues and
cells [58], and they are well established carrier systems with
high potential for the delivery of bioactive macromolecules,
including peptides, proteins, and nucleic acid vaccines
[59]. Encapsulation in the polymers allows maintaining the
integrity and activity of these biomolecules, protecting them
from exposure to extreme pH conditions, bile and panc-
treatic secretions, and augments the immunopotentiating
effect of the antigens [60].
It is well known that properties of nanoparticles such
as size, surface charge, hydrophobicity/hydrophilicity, and
steric effects of particle coating can determine its compati-
bility with the immune system [61–63].
Furthermore, nanoparticles can also be designed to
provoke an immune response, by either direct immunostim-
ulation of antigen presenting cells or delivering antigens to
specific cellular compartments [64].
For the obtention of the desired therapeutic response,
size particle control is important since microparticles are
rapidly cleared by reticuloendothelial system, while nanopar-
ticles have prolonged circulation time and are efficient drug,
enzyme, and protein carriers by any route of administration
[65, 66].
Furthermore, in order to achieve the desired therapeutic
response with these biodegradable polymeric devices, it
is also important, to select the right polymer to be used
as an encapsulating agent, since its nature significantly
influences the size and the release profile of the nanoparticles
[67]. These biodegradable polymers can be either natural
(chitosan, alginate, carrageenan, albumin, gelatin, collagen,
among others) or synthetic [poly(lactic acids), PLA),
poly(lactide-co-glycolic acids), PLGA), poly(methyl meth-
acrylate), PMMA), poly(ε-caprolactone), PCL), poly(alkyl-
cyanoacrylates), PACA), and copolymers]. The former gen-
erally provide a relatively quick drug release, while the latter
enable extended drug release over periods from days to
several weeks [67, 68]. However, the use of synthetic polymer
can be limited due to the need of organic solvents and harsh
formulation conditions [58, 68]. The most commonly and
extensively used polymeric nanoparticles for vaccine pur-
poses are described in this section.
5.1.1. Polyesters. Polyesters are thermoplastic polymers with
hydrolytically labile aliphatic ester linkages in their structure.
Although all polyesters are theoretically degradable, only
aliphatic ones with short aliphatic chains between ester
bonds can degrade in the time required for most of the
biomedical application [69]. These polymers are the most
used biodegradable polymers as drug-delivery systems and
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have attracted considerable attention as drug carriers due to
their biocompatibility and biodegradability.
(1) Polylactides. For vaccination purposes, polyesters such as
PLA and PLGA (of variableMWand composition) have been
the most popular materials for the preparation of polymer
nanoparticles [70]. Due to its well-documented biocompat-
ibility, safety, and biodegradability, these polymers are FDA
approved for several clinical applications in humans [59].
PLGA is a polyester composed by of one or more of three
different hydroxy acid monomers, d-lactic, l-lactic, and/or
glycolic acids [71]. These copolymers undergo hydrolysis of
its ester groups in the presence of water, and the degradation
time depends on the LA : GA monomer ratio (50 : 50 up
to 100 : 0), molecular mass, end functional group (free or
esterified carboxylic acid), and the shape and structure of the
matrix [69]. These parameters also determine the encapsula-
tion efficiency and release rate of drugs and antigens from
this material [72]. For instance, it has been demonstrated
that nanoparticles prepared from a 75 : 25 PLGA copolymer
(a slow degradation rate polymer) presented slower release
rate of antigen than those prepared from a 50 : 50 PLGA
copolymer (a fast degradation rate polymer) [73].
The application of these polymeric particles to antigen
delivery has been widely investigated from the early 90s
[59]. Several authors have reported that due to its ability
to efficiently target professional antigen presenting cells
(APCs), the effects of PLGA entrapped antigen on the cellular
and humoral immune response have several times been
shown to be superior to application of soluble, free antigen
[74–77].
Thus, both nano- and microparticles of PLGA can be
used to increase and modulate immune responses against
encapsulates antigens and to facilitate appropriate processing
and presenting antigens to T cells [78–80]. Therefore, in
recent years, these polymers have been studied for allergen-
delivery use, finding that the PLGA nanoparticles are of
great interest for therapy of allergies [81–83]. As an example,
PLGA nanoparticles loaded with Bet v1 (the major allergen
of birch pollen) reduce the predominance of the TH2
response, increasing the Bet v1 IgG2a levels, concomitant
with an increase in IFN-γ and IL-10 levels [82, 83].
Other less commonly used polylactide particles include
poly(DL-lactide glycolide) or PLG microparticles that are
also able to induce CD8+ T cell responses [84]. These
particles have been used as a vehicle for Ole e 1, the main
olive pollen allergen, in the desighning of allergen-specific
vaccine [85].
Despite its obvious interest as nanoparticulate adjuvants
and delivery systems for immunotherapy, the use of these
polymers as peptide or protein delivery may negatively
affect the stability of the loaded compound due to the
bulk degradation mechanism of the polymer and the acidic
degradation obtained products [59, 69, 86–89]. Another
limitation of these nanoparticles is their insufficient stability
and penetration capacity upon mucosal administration [59].
Thus, recent research has been focused on the search
for additional strategies to improve the efficiency of these
nanoparticles by addressing its limitations. Overall, most of
these strategies involve the modification of the surface of
the particles by using a suitable stabilizer. The substance
most commonly used for this purpose is poly(ethylene
glycol) (PEG) [59], which is a hydrophilic, non-ionic, and
biocompatible polymer that can be added to the particles
by different routes, including covalent bonding and mixing
during nanoparticle preparation or surface adsorption [90].
For instance, it was demonstrated that PLA-PEG nanopar-
ticles, with a high PEG coating density and small size, are
significantly better transporters across the nasal mucosa than
noncoated PLA and even than PLA-PEG nanoparticles with
a lower coating density [91].
Different studies have been performed using these
nanoparticles for vaccine purposes. For example, it has been
demonstrated that recombinant hepatitis B surface antigen
encapsulated within PEGylated PLGA nanoparticles allows
generating very fast immune responses compared to the
non encapsulated antigen counterpart [92]. Other authors
achieved an enhancement of the transport of the PEG-PLA
nanoparticles encapsulated tetanus toxin across the intestinal
barrier [93, 94].
(2) Poly(ε-Caprolactone). Poly(ε-caprolactone) (PCL) is a
biocompatible, bioerodable, biodegradable and semicrys-
talline polyester that can be used for the formulation
of nanoparticles [68]. Due to the semicrystallinity and
hydrophobicity, the in vivo degradation of PCL is much
slower than PLGA, making it more appropriate for long-
term delivery systems, extending over a period of more
than one year [58, 95]. Furthermore, PCL particles, unlike
polylactides, do not generate an acidic environment that
could negatively affect the antigenicity of the encapsulated
antigens or allergens [96].
However, most of the PCL studies found in the field of
immunotherapy have been performed using PCL micropar-
ticles/microspheres [95]. Studies that use this polymer as
nanoparticles for allergen immunotherapy have not been
found and it has been little used as nanoparticulate adju-
vant system for vaccine development. For example, PCL
nanospheres together with mucoadhesive polymers (alginate
or chitosan) were used as a potential carrier for Streptococcus
equi surface proteins. Serum IgG antibody levels of animals
vaccinated with S. equi antigens encapsulated or adsorbed
onto PCL particles were significantly higher than those
caused by free antigens or even free antigens adjuvanted with
cholera toxin B subunit [97]. Thus, although no examples
of the use of PCL nanoparticles for allergen immunotherapy
were found, the good results obtained by different authors
by using these PCL-nanoparticles in the field of vaccination
suggest these systems as potential adjuvants in allergen
immunotherapy.
5.1.2. Poly(Anhydrides). In contrast to polylactide nanopar-
ticles, the degradation products of polyanhydrides are non-
cytotoxic and less acidic than those of polyesters, which
can improve the stability of encapsulated antigen [88].
The copolymers between methyl vinyl ether and maleic
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anhydride (PVMA) (commercialized as Gantrez AN from
ISP, Corp.) are a good example of these polyanhydrides. Due
to the presence of reactive anhydride groups which do not
need time-consuming chemical activation, this copolymer
allows to easily prepare nanoparticles under mild conditions,
using a solvent displacement method [98]. Moreover, a
recent research concluded that the use of Gantrez AN 119
nanoparticles prepared by using reduced amount of organic
solvent (acetone) facilitates the encapsulation of the antigen
and offers a mild irritation at mucosal epithelia when orally
unstabilised nanoparticles are used [99].
One of the most important properties of the Gantrez
nanoparticles is their ability to develop strong bioadhesive
interactions with components of the gut mucosa [100]. In
addition, their surface can be easily modified by simple incu-
bation with different excipients or ligands in order to modify
their in vivo distribution [101, 102], and even to increase its
affinity for the intestinal mucosa [100]. This makes Gantrez
nanoparticles good candidates for oral immunotherapy
treatments, which have many evident advantages (patient
compliance, safest route, least expensive route etc). In fact,
some studies have demonstrated the efficacy of these particles
by this route. For example, Go´mez and coworkers [103]
found enhancements in both TH1 and TH2 markers (IgG2a
and IgG1, resp.) after oral administration Gantrez AN
nanoparticles loaded with ovalbumin as allergen model.
Moreover, these carriers were able to protect a model of
sensitized mice to ovalbumin from anaphylactic shock. Thus,
these PVMA nanoparticles have been widely used as carriers
for controlled delivery of antigens such as Lolium perenne
(allergenic proteins of rye-grass pollen) (N), [88, 103–106].
Another advantage of this copolymer is that it can easily
react with amino groups, which makes easy to load or link
different types of immunostimulants, like proteins or even
lipopolysaccharides.
Also, the loading of antigens into these bioadhesive
nanoparticles has demonstrated to enhance the immune
responses in terms of a potent TH1 adjuvant capacity
[103, 105, 107]. This strong response may be due to the
effect produced by the nanoparticles that promote close
interactions between antigen and antigen-presenting cells,
and also act as agonists of various Toll-like receptors (TLRs),
mainly TLR2 and TLR 4 [86, 108].
Other polyanhydrides based on hydrophobic moieties
or on oligomeric ethylene glycol-containing anhydrides
have been shown promise as novel vaccine carriers with
immunomodulatory capabilities [88].
5.1.3. Poly(Gamma-Glutamic Acid). Poly(gamma-glutamic
acid) (γ-PGA) is a high molecular weight polypeptide
composed of γ-linked glutamic acid units and α-carboxylate
side chains produced by certain strains of Bacillus [109]. Due
to the amphiphilic nature of the hydrophobically modified
γ-PGA copolymer, it is possible to form nanoparticles with
a simple methodology [110]. In recent years, a research
group has developed biodegradable nanoparticles using γ-
PGA with L-phenylalanine ethyl ester and evaluated the
feasibility of protein entrapment on/into this carriers as well
as their biological potential. As a result of these rechearches,
ovalbumin (OVA), as a model protein, was successfully
encapsulated in these nanoparticles, which also did not
induce any cytotoxicity against HL-60 cells [109].
Subsequent studies also showed that these particles are
activators of human monocyte-derived dendritic cells and
strongly stimulate the production of chemokines and inflam-
matory cytokines as well as upregulation of costimulatory
molecules and immunomodulatory mediators involved in
efficient T cell priming. Furthermore, in vitro studies with
monocyte-derived dendritic cells and grass pollen allergen
Phleum pratense loaded γ-PGA nanoparticles showed an
increase allergen-specific IL-10 production and proliferation
of autologous CD4+ memory T cells [110].
Additionally, studies show that these biodegradable
nanoparticles induce in vitro innate immune cell activation,
produce antigen-specific immune responses in vivo through
the TLR 4 andMyD88-dependent signaling pathway, and can
influence innate and adaptive immune responses by first-line
host sensor [111].
In conclusion, these systems seem to be a new and
good adjuvants and antigen carriers for allergen-specific im-
munotherapy.
5.1.4. Poly(Vinylpyrrolidone). Although fewer employees
than polymers described before, there are some studies that
suggest the interest of using poly(vinylpyrrolidone) (PVP)
for the obtention of promising allergen-delivery nanocar-
riers. For example, Madan and coworkers [112] showed a
successful entrapment of antigens of Aspergillus fumigatus
(pathogenic fungi responsible of several allergic diseases) and
found a sustained IgG antibody levels for approximately 12
weeks in comparison to IgG levels for 7 days with free antigen
after immunization of male BALB/c mice. Moreover, IgE
levels of allergens loaded PVP nanoparticles were lower than
observed in free allergens studies.
5.1.5. Polysaccharides. The most investigated polysaccha-
ride for mucosal vaccine delivery is chitosan, poly(D-glu-
cosamine). This polymer is prepared by the partial N-
deacetylation of chitin, a natural polymer, the second most
abundant natural polysaccharide in nature, which is derived
from the cuticles of insect species or crustaceans such as crabs
and shrimp [113].
Chitosan is soluble in weekly acid solutions, resulting
in the formation of a cationic polymer with high charge
density, and can therefore form polyelectrolyte complexes
with a large variety of anionic polymers [69]. Besides, due
to the presence of highly reactive amino groups along its
structure, chitosan is susceptible to chemical or biological
functionalization [114]. Also, the preparation of chitosan
nanoparticles based on the basis this polymer can be easily
done without the use of organic solvents, which is interesting
to maintain the immunogenicity of the antigens [115].
Chitosan possesses other advantageous properties such
as low production costs, biocompatibility, biodegradability,
and nontoxicity that, along with its ability to enhance the
penetration of macromolecules across the intestinal and
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nasal barriers, make it a suitable candidate for the design
of mucosal vaccine formulations [68, 69, 116–119]. Thus,
slowed mucociliary transport as well as a transient increase
in paracellular absorption should lead to an improved
immunological response [115].
Several studies have reported the use of chitosan-
based nanocarriers for gene delivery [120–122]. CS-based
nanocomplexes have been developed for the targeted delivery
of plasmid DNA (pDNA) and also as carriers for RNA [122,
123].
Chitosan nanoparticles incorporating soluble antigens as
diphtheria and tetanus toxoids and plasmid DNA induced
high and long-lasting IgG immune responses, demonstrating
the effectiveness of these devices for intranasal vaccination
[93, 124]. This significant systemic and mucosal immune
response enhancement after nasally administered chitosan
nanoparticles has been demonstrated also for influenza,
pertussis, and diphtheria vaccines [115, 124]. However, until
now, the mechanism by which the antigen is delivered
to the nasal mucosa and the role of the physicochemical
characteristics of the particles in this processes have not been
well determined, and there is some contradictory theories
[124].
For oral vaccination studies, Roy and coworkers have
demonstrated the effectiveness of orally delivered chitosan-
DNA nanoparticles in inducing protective immunity in
the peanut allergy mouse model [125]. More specifically,
chitosan nanoparticles loaded with the gene for Ara h2 (main
peanut allergen) allow to obtain a significant reduction in the
levels of serum IgE, plasma histamine, and vascular leakage
and the induction of specific mucosal IgA antibodies.
Other studies show a significant amelioration of
ovalbumin-induced food allergy symptoms when the TGF-
beta expressing DNA vector is orally administered after its
encapsulation in chitosan nanoparticles, compared to the
previously reported protein-based strategies [126].
However, in spite of all the described advantageous
properties of chitosan, this polymer has a major limitation:
its low solubility at physiological pH and therefore loses
of its ability to enhance drug permeability and absorption
[127, 128].
To improve this drawback, several derivatives of chitosan
have been studied, such as trimethyl chitosan (TMC), that
shows high solubility, bioadhesive properties, and ability
to enhance permeability over a wide pH range [129, 130].
In fact, a recent study shows that trimethylated chitosan
nanoparticles obtained by using a new mild method induced
stronger humoral and mucosal immune responses compared
to generate by chitosan conventional nanoparticles [131].
Other interesting alternative is the use of chitosan
together with other biodegradable polyelectrolyte polymers
with opposite charge to obtain combined nanoparticles suit-
able for mucosal vaccinations. A typical example of this sec-
ond polymer can be sodium alginate, another biodegradable
and biocompatible polysaccharide. For instance, it has been
demonstrated that alginate-chitosan-coated nanoparticles
are an effective system for subcutaneous and oral vaccination
with the recombinant hepatitis B surface antigen [132–134].
Another study shows that these nanoparticles can prevent a
burst release of loaded ovalbumin and improve its stability in
simulated intestinal fluid at 37◦C [132].
5.2. Nondegradable Polymeric Nanoparticles. Nondegradable
nanoparticles of different materials such as latex, gold, silica,
or polystyrene are being evaluated as antigen carriers for
induction of immunity [70, 77, 135]. It is considered that
by using these particles, the antigen can be presented to
the immune system for extended periods of time, and
thus improve the immunogenicity, probably due to the
persistence of the nanoparticles in the tissues [70, 77].
On the other hand, these polymers have several techno-
logical advantages [64]. For example, polystyrene nanopar-
ticles can be made with several functional groups on their
surface to achieve effective conjugation with a variety of anti-
gens. Furthermore, when the antigen is covalently coupled to
the particle, it induces higher cellular and humoral responses
than in the cases where the antigen is absorbed [136].
For latex particles, some examples in the literature
have demonstrated that this polymer was presented 1000–
10,000-fold more efficiently by MHC-Class I molecules than
soluble antigens [137] or antigens presented via MHC-
Class II molecules [138]. Gold nanoparticles also appear to
enhance the effect of DNA vaccination by improving delivery
onto cellular interiors [139]. However, these results are
obtained using electroporation, which may not be applicable
in humans due to cell mortality. In the absence of this
technique, so by passive diffusion, the immunological effects
were not so interesting [140]. Other recent studies show that
the use of gold nanoparticles along with alum can enhance
the immune response against PfMSP-119 and PvMSP-119
[141].
However, in general terms, it was shown that nondegrad-
able particles were much less effective at cross-presenting
antigens than degradable ones [142, 143]. Also, to use this
type of nanoparticles for vaccination purposes is necessary
to consider aspects of toxicity and particles aggregation in the
tissues, which requires follow-up studies of in vivo clearance
and the determination of possible adverse effects resulting
from its use [77].
6. Conclusion
In summary, the use of nanotechnology platforms, although
widespread in recent years for vaccination purposes [98,
106], is emerging in the field of allergen immunotherapy
[103–105]. Given the promising results obtained so far,
polymeric nanoparticles can be of interest to develop new
therapeutic strategies able to improve both clinical efficacy
and safety of allergen vaccines.
On the other hand, our knowledge of the nanoparticle
interaction with the immune system has been increased
in recent years, but it still remains insufficient. Thus,
further studies related to the immunomodulatory effects of
the polymeric nanoparticles are required to improve our
understanding, and therefore our capability, to design better
specific and effective allergen vaccines.
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